Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4232 |
Name | extraosseous Ewing sarcoma |
Definition | A Ewing sarcoma that is morphologically indistinguishable from skeletal Ewing sarcoma but is located in extraosseous locations. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer Ewing sarcoma extraosseous Ewing sarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01492673 | Phase II | Bevacizumab + Cyclophosphamide + Topotecan | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | Completed | USA | CAN | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01610570 | Phase Ib/II | Plicamycin | Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | Terminated | USA | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01661400 | Phase I | Cyclophosphamide Thalidomide | Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors | Completed | USA | 0 |
NCT02511132 | Phase II | FANG vaccine Docetaxel + Gemcitabine FANG vaccine + Irinotecan + Temozolomide | A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma | Completed | USA | 0 |